Our Pricing

Expert Tips for Mounjaro Clicks Chart Success

Mastering mounjaro clicks chart UK tips is essential for safe, effective treatment with tirzepatide. At Cured Pharmacy, our UK-registered clinical team helps thousands of patients navigate the Mounjaro KwikPen system, from understanding click increments to optimising dose escalation schedules. This comprehensive guide provides expert insights to maximise your treatment success.

Understanding the Mounjaro Clicks Chart System

The Mounjaro KwikPen uses a precise click mechanism to deliver accurate tirzepatide doses, with each click representing a specific increment of medication [1]. Unlike older injection systems, the pen is pre-filled and designed for single-dose administration, eliminating the need for manual dose selection. Understanding how the clicks correspond to your prescribed dose ensures you receive the correct amount of active ingredient with each injection.

Each Mounjaro pen is calibrated to deliver one complete dose when the plunger is fully depressed. The audible and tactile clicks you hear during injection confirm the pen mechanism is functioning correctly. According to MHRA-approved prescribing information, the pen should be held against the skin for at least 10 seconds after the dose counter reaches zero to ensure complete delivery [1][2].

UK prescribers typically initiate treatment at 2.5mg weekly, with dose escalation every four weeks based on individual tolerance and response. The clicks chart serves as a reference point for patients to verify their pen corresponds to the correct prescribed strength, as each dose increment (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg) comes in a separately labelled pen.

Mounjaro Dose Escalation Schedule Explained

Clinical trials including SURPASS-1 through SURPASS-5 demonstrated that gradual dose escalation minimises gastrointestinal side effects whilst optimising weight loss outcomes [1][3]. The standard UK escalation protocol begins with 2.5mg weekly for four weeks, increasing to 5mg for the next four weeks, then progressing through 7.5mg, 10mg, 12.5mg, and finally 15mg if clinically appropriate.

Your UK prescriber will determine the optimal maintenance dose based on your response, tolerability, and weight loss trajectory. In the SURMOUNT-1 trial, patients who reached the 15mg maintenance dose achieved an average 22.5% body weight reduction over 72 weeks, though many patients achieve their goals at lower doses [1]. Not every patient requires escalation to the maximum dose—your clinical team will assess whether continued escalation is necessary or whether maintaining your current dose is more appropriate.

Recognising When to Pause Dose Escalation

If you experience persistent nausea, vomiting, or diarrhoea lasting more than 72 hours, contact your prescriber before escalating to the next dose. The UK clinical guidance recommends remaining at your current dose for an additional four weeks if gastrointestinal symptoms are moderate to severe [2]. This approach maintains treatment efficacy whilst improving tolerability, as abrupt escalation can lead to treatment discontinuation.

Proper Injection Technique for Mounjaro Pens

Correct injection technique significantly impacts treatment comfort and medication absorption. The Mounjaro KwikPen should be injected subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy [2]. Before injecting, allow the pen to reach room temperature for at least 30 minutes after removing it from refrigeration—cold injections cause unnecessary discomfort and may affect absorption rates.

Pinch the skin gently to create a fold, insert the needle at a 90-degree angle, and press the dose button firmly until you hear the first click. Continue holding the pen against your skin until the dose counter returns to zero and you've counted to ten. Many patients make the mistake of removing the pen too quickly, which can result in incomplete dose delivery and reduced efficacy [2].

After injection, do not rub the site—simply apply gentle pressure with a clean cotton pad if needed. Dispose of used pens in a sharps container, which your pharmacy can provide. Never attempt to reuse a Mounjaro pen or share it with another person, even if the needle is changed.

Troubleshooting Common Pen Issues

If your pen doesn't click or the dose counter doesn't move, check that you've removed both the outer and inner needle caps before injecting. If the pen appears damaged, has been frozen, or has been stored above 30°C, do not use it—contact Cured Pharmacy on (+44) 116 4646009 for a replacement. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team can assess whether a replacement pen is required under your prescription.

How Mounjaro Compares to Other Weight Loss Treatments

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist licensed in the UK, offering a different mechanism compared to semaglutide-based treatments like Wegovy [1][3]. By activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide produces enhanced effects on appetite regulation, glucose metabolism, and energy expenditure.

Head-to-head trials showed tirzepatide achieved superior weight loss outcomes compared to semaglutide 1mg in patients with type 2 diabetes, with the 15mg tirzepatide dose producing approximately 5-7% greater body weight reduction than semaglutide 1mg [3]. Both medications require once-weekly subcutaneous injection and follow similar dose escalation protocols to minimise side effects.

For patients who prefer daily injections or have previously used liraglutide-based treatments, Saxenda remains a licensed option in the UK. However, clinical data demonstrates that once-weekly GLP-1 receptor agonists like Mounjaro and Wegovy produce greater average weight loss than daily liraglutide, likely due to improved adherence and higher therapeutic doses [3][4].

Managing Side Effects During Dose Escalation

Gastrointestinal side effects including nausea, diarrhoea, constipation, and reduced appetite are the most commonly reported reactions during Mounjaro treatment, particularly during dose escalation phases [1][2]. These effects typically peak within the first few days after injection and diminish as your body adapts to each new dose level.

To minimise nausea, eat smaller, more frequent meals rather than large portions, avoid high-fat or spicy foods, and stay well-hydrated throughout the week. Ginger tea, plain crackers, and cold foods are often better tolerated during periods of nausea. If symptoms persist beyond 72 hours or prevent adequate nutrition and hydration, contact your prescriber—they may recommend remaining at your current dose for longer before escalating [2].

Constipation can be managed by increasing dietary fibre intake, drinking at least two litres of water daily, and maintaining regular physical activity. Over-the-counter remedies like lactulose or ispaghula husk may help, but consult your pharmacist before combining them with Mounjaro. Severe or persistent constipation lasting more than one week should be reported to your clinical team.

When to Contact Your Prescriber Urgently

Seek immediate medical attention if you experience severe abdominal pain (particularly in the upper abdomen radiating to the back), persistent vomiting preventing fluid intake, signs of pancreatitis, or symptoms of thyroid tumours such as a lump in the neck or difficulty swallowing [2]. Whilst these serious adverse events are rare, early recognition and intervention are essential. Your UK prescriber can be reached through your Cured Pharmacy patient portal for non-urgent clinical queries.

Maximising Weight Loss Results with Mounjaro

Clinical trials demonstrate that Mounjaro produces optimal outcomes when combined with a reduced-calorie diet and increased physical activity [1][3]. Whilst the medication significantly reduces appetite and promotes satiety, sustainable weight loss requires behavioural modifications that extend beyond pharmacotherapy alone. UK clinical guidelines recommend aiming for a 500-600 calorie daily deficit alongside Mounjaro treatment.

Focus on protein-rich foods to preserve lean muscle mass during weight loss, as tirzepatide's effects on appetite can sometimes lead to inadequate protein intake if not carefully monitored. Aim for 1.2-1.6 grams of protein per kilogram of ideal body weight daily, distributed across meals. Resistance training at least twice weekly helps maintain metabolic rate and prevents the muscle loss that often accompanies significant weight reduction [4].

Track your progress using multiple metrics beyond the scale—measurements, clothing fit, energy levels, and metabolic markers like HbA1c and lipid profiles provide a comprehensive picture of treatment success. Most patients begin noticing appetite suppression within the first week of treatment, with measurable weight loss typically evident by week four. The SURMOUNT trials showed that weight loss continues progressively through 72 weeks, with the greatest reductions observed in patients who reached higher maintenance doses [1][3].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. UK Public Assessment Report.
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine in the UK and must be prescribed following appropriate clinical evaluation. Individual results may vary, and not all patients will be suitable for treatment with tirzepatide.